2025-11-16 - Analysis Report
Okay, here's an analysis of Merck & Co Inc (MRK) based on the provided data, formatted as requested:

## MRK (Merck & Co Inc) Analysis

Merck & Co Inc is a global pharmaceutical company that discovers, develops, manufactures, and markets a wide range of healthcare products.

### 1. Performance vs. S&P 500 (VOO)

*   **MRK Cumulative Return:** 9.84%
*   **VOO Cumulative Return:** 98.45%
*   **Performance Differential:**
    *   Current: -99.8
    *   Range: Max 23.9, Min -104.3
    *   Relative Differential: 3.5 (Indicates MRK's current underperformance is near the bottom of its historical range relative to VOO.)

**Analysis:** MRK has significantly underperformed the S&P 500 (VOO) based on cumulative returns. The Relative Differential suggests that while MRK is currently underperforming, it's near the lowest end of its historical underperformance range.

**Alpha, Beta Analysis:**

| Year       | CAGR   | MDD    | Alpha   | Beta  | Cap(B) |
|------------|--------|--------|---------|-------|--------|
| 2015-2017  | 1.0%   | 68.5%  | -27.0%  | 0.2   | 133.3  |
| 2016-2018  | 36.0%  | 69.8%  | 21.0%   | 0.3   | 181.0  |
| 2017-2019  | 40.0%  | 69.8%  | 18.0%   | 0.3   | 215.4  |
| 2018-2020  | 16.0%  | 79.6%  | -8.0%   | 0.3   | 193.8  |
| 2019-2021  | 2.0%   | 79.6%  | -44.0%  | 0.7   | 190.2  |
| 2020-2022  | 15.0%  | 79.6%  | 16.0%   | 0.7   | 275.4  |
| 2021-2023  | 33.0%  | 79.6%  | 31.0%   | 0.3   | 270.6  |
| 2022-2024  | -4.0%  | 79.6%  | -25.0%  | 0.2   | 246.9  |
| 2023-2025  | -39.0% | 71.5%  | -102.0% | 1.7   | 230.7  |

**Analysis:**

*   **CAGR:** Fluctuating CAGR (Compound Annual Growth Rate) indicates inconsistent growth over the periods. Recent years (2022-2025, 2023-2025) show negative growth.
*   **MDD:** High Maximum Drawdown (MDD) values consistently indicate significant potential for loss from peak to trough.
*   **Alpha:** Alpha is inconsistent, with positive values in some periods (2016-2019, 2020-2023) suggesting outperformance relative to the benchmark, and negative values indicating underperformance. The very negative Alpha in 2023-2025 is concerning.
*   **Beta:** Beta values are relatively low and stable, indicating that MRK's price is generally less sensitive to market movements than the S&P 500. However, the spike to 1.7 in 2023-2025 suggests increased volatility relative to the market in that period.
*   **Cap:** The Capitalization (Cap) values show fluctuating market capitalization, with significant growth followed by decline.

### 2. Recent Price Action

*   **Current Price:** 92.92
*   **Previous Close:** 92.93
*   **Change:** -0.01 (Slightly negative change)
*   **5-Day Moving Average:** 91.0
*   **20-Day Moving Average:** 87.3945
*   **60-Day Moving Average:** 85.1568

**Analysis:** The price is slightly down from the previous close. The price is above all the moving averages, suggesting an upward trend, with the short-term moving average (5-day) above the longer-term moving averages (20-day and 60-day).

### 3. Technical Indicators

*   **Market Risk Indicator (MRI):** 0.8 (Medium Investment Recommended)
*   **RSI:** 65.41 (Approaching overbought territory)
*   **PPO:** 0.8652 (Positive, indicating upward momentum)
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (11 shares - Very Safe - MRI:0.90)
*   **Recent Relative Divergence Change (20-day):** 1.6 (+) (Short-term upward trend)
*   **Expected Return (%):** -209.8 (Significantly negative, suggesting long-term underperformance relative to S&P 500)

**Analysis:** The MRI suggests a medium investment recommendation. The RSI is approaching overbought conditions, which could indicate a potential pullback. The PPO indicates positive momentum. The significant negative Expected Return is a major concern, suggesting a substantial expected underperformance against the S&P 500 over the long term. The negative change near previous close may signal a short-term issue.

### 4. Recent News & Significant Events

*   **Cidara Therapeutics Acquisition:** Merck's $9.2 billion acquisition bid for Cidara Therapeutics has caused CDTX to skyrocket.
*   **Marks Electrical Group:** Mentions Marks Electrical Group (LON:MRK), *but this is a different company* and likely irrelevant.
*   **Buyout Bonanza:**  Reinforces the Cidara acquisition.
*   **Sector Update:**  A general health care sector update.

**Analysis:** The Cidara Therapeutics acquisition is a significant event and positive news for Merck. It shows Merck is actively pursuing growth opportunities.

### 4-2. Analyst Opinions

*   **Consensus:** Buy
*   **Mean Rating:** 2.04 (~Buy)
*   **Opinions:** 25 analysts
*   **Target Price:**
    *   Average: 102.32
    *   High: 137.00
    *   Low: 82.00

**Analysis:** Analyst sentiment is generally positive, with a "Buy" consensus and an average target price above the current price. However, the wide range between high and low target prices indicates some uncertainty among analysts.

### 5. Recent Earnings Analysis

| 날짜       | EPS  | 매출      |
|------------|------|-----------|
| 2025-11-05 | 2.32 | 17.28 B$  |
| 2025-08-05 | 1.76 | 15.81 B$  |
| 2025-05-02 | 2.01 | 15.53 B$  |
| 2024-11-06 | 1.25 | 16.66 B$  |
| 2025-11-05 | 1.25 | 16.66 B$  |

**Analysis:**
The most recent EPS (2.32) and revenue (17.28 B$) show positive growth compared to previous quarters. The fluctuation in EPS and revenue suggests that the company's performance is variable.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2025-09-30   | $17.28B   | 77.69%        |
| 2025-06-30   | $15.81B   | 77.50%        |
| 2025-03-31   | $15.53B   | 77.98%        |
| 2024-12-31   | $15.62B   | 75.50%        |
| 2024-09-30   | $16.66B   | 75.51%        |

**Analysis:** Revenue has generally been increasing, and profit margins are consistently high (above 75%), indicating strong profitability.

**Capital and Profitability:**

| Quarter      | Equity    | ROE     |
|--------------|-----------|---------|
| 2025-09-30   | $51.85B   | 11.16%  |
| 2025-06-30   | $48.99B   | 9.04%   |
| 2025-03-31   | $48.34B   | 10.51%  |
| 2024-12-31   | $46.31B   | 8.08%   |
| 2024-09-30   | $44.50B   | 7.09%   |

**Analysis:** Equity is growing, and ROE (Return on Equity) is fluctuating but generally improving, indicating increasing profitability relative to shareholder equity.

### 7. Overall Summary

Based on the provided data, here's a summary of MRK's situation:

*   **Underperformance:** MRK has significantly underperformed the S&P 500 in cumulative returns.
*   **Financials:** Strong revenue, high profit margins, and growing equity are positive indicators.
*   **Recent News:** The acquisition of Cidara Therapeutics is a positive catalyst.
*   **Technicals:** Short-term upward trend, but RSI is approaching overbought.
*   **Analyst Sentiment:** Generally positive, with a "Buy" consensus and target price above the current price.
*   **Expected Return:** The significantly negative expected return is a major red flag.
*   **Alpha and Beta:** Fluctuating alpha and MDD, and rising beta in recent years, indicates inconsistent performance and high potential for loss.

**Conclusion:** While MRK shows some positive signs (strong financials, a recent acquisition, analyst support), the significant underperformance compared to the S&P 500 and the highly negative expected return are serious concerns. Furthermore, the high MDD and volatile alpha and beta indicates high risks.
